Brain biochemistry using magnetic resonance spectroscopy: Relevance to psychiatric illness in the elderly

Journal of Geriatric Psychiatry and Neurology

Volumn 12, Issue 3, 1999, Pages 107-117

  Moore, Constance M ^a,b   Frederick, Biaise DeB ^a,b   Renshaw, Perry F ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHORUS 31; PROTON;

AGING; ALZHEIMER DISEASE; AMNESIA; BIOCHEMISTRY; BRAIN METABOLISM; CLINICAL TRIAL; DEMENTIA; DEPRESSION; DOWN SYNDROME; ELECTROCONVULSIVE THERAPY; FRONTOTEMPORAL DEMENTIA; GERONTOPSYCHIATRY; HUMAN; MENTAL DISEASE; MULTIINFARCT DEMENTIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; REVIEW; SPECTROSCOPY;

EID: 0033385863     PISSN: 08919887     EISSN: None     Source Type: Journal    
DOI: 10.1177/089198879901200304     Document Type: Review

References (96)

1. Barker PB, Butterworth EJ, Boska MD, et al. Magnesium and pH imaging of the human brain at 3.0 Tesla. Magn Reson Med 1999; 41:400-406.
2. Hetherington HP, Pan JW, Chu WJ, et al. Biological and clinical MRS at ultra-high field. NMR Biomed 1997; 10:360-371.
3. Cady EB. Clinical magnetic resonance spectroscopy. New York: Plenum, 1990.
4. Buchli R, Duc CO, Martin E, et al. Assessment of absolute metabolite concentrations in human tissue by 31P MRS in vivo. Part I: cerebrum, cerebellum, cerebral gray and white matter. Magn Reson Med 1994; 32:447-452.
5. Gyulai L, Bolinger L, Leigh JS Jr, et al. Phosphorylethanolamine - the major constituent of the phosphomonoester peak observed by 31P-NMR on developing dog brain. FEBS Lett 1984; 178:137-142.
6. Kilby PM, Bolas NM, Radda GK. 31P-NMR study of brain phospholipid structures in vivo. Biochim Biophys Acta 1991; 1085: 257-264.
7. Lim KO, Pauly J, Webb P, et al. Short TE phosphorus spectroscopy using a spin-echo pulse. Magn Reson Med 1994; 32:98-103.
8. Tortora G, Anagnostakos N. Principles of anatomy and physiology. New York: Harper and Row, 1987.
9. Veech RL, Lawson JW, Cornell NW, et al. Cytosolic phosphorylation potential. J Biol Chem 1979; 254:6538-6547.
10. Chance B. Metabolic heterogeneities in rapidly metabolizing tissues. J Appl Cardiol 1989; 4:207-221.
11. Petroff OA, Prichard JW, Behar KL, et al. Cerebral intracellular pH by 31P nuclear magnetic resonance spectroscopy. Neurology 1985; 35:781-788.
12. Dager SR, Steen RG. Applications of magnetic resonance spectroscopy to the investigation of neuropsychiatric disorders. Neuropsychopharmacology 1992; 6:249-266.
13. Birken DL, Oldendorf WH. N-acetyl-L-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev 1989; 13:23-31.
14. Tsai G, Coyle JT. N-acetylaspartate in neuropsychiatric disorders. Prog Neurobiol 1995; 46:531-540.
15. Koller KJ, Zaczek R, Coyle JT. N-acetyl-aspartyl-glutamate: regional levels in rat brain and the effects of brain lesions as determined by a new HPLC method. J Neurochem 1984; 43: 1136-1142.
16. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991; 45:37-45.
17. Petroff OA, Spencer DD, Alger JR, et al. High-field proton magnetic resonance spectroscopy of human cerebrum obtained during surgery for epilepsy. Neurology 1989; 39:1197-1202.
18. Zeisel SH. Choline phospholipids: signal transduction and carcinogenesis. FASEB J 1993; 7:551-557.
19. Miller BL, Chang L, Booth R, et al. In vivo 1H MRS choline: correlation with in vitro chemistry/histology. Life Sci 1996; 58: 1929-1935.
20. Barker PB, Breiter SN, Soher BJ, et al. Quantitative proton spectroscopy of canine brain: in vivo and in vitro correlations. Magn Reson Med 1994; 32:157-163.
21. Charles HC, Lazeyras F, Krishnan KR, et al. Brain choline in depression: in vivo detection of potential pharmacodynamic effects of antidepressant therapy using hydrogen localized spectroscopy. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18:1121-1127.
22. Stoll AL, Renshaw PF, De Micheli E, et al. Choline ingestion increases the resonance of choline-containing compounds in human brain: an in vivo proton magnetic resonance study. Biol Psychiatry 1995; 37:170-174.
23. Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1989; 59:411-419.
24. Klunk WE, Xu CJ, Panchalingam K, et al. Analysis of magnetic resonance spectra by mole percent: comparison to absolute units. Neurobiol Aging 1994; 15:133-140.
25. Jarvik L, Small G. Geriatric psychiatry: introduction and overview. In: Kaplan H, Sadock B, eds. Comprehensive textbook of psychiatry. Vol. 2. Baltimore: Williams & Wilkins, 1995:2507-2513.
26. Henderson S. Geriatric psychiatry: epidemiology of psychiatric disorders. In: Kaplan H, Sadock B, eds. Comprehensive textbook of psychiatry. Vol. 2. Baltimore; Williams & Wilkins, 1995:2513-2519.
27. Small G. Psychiatric disorders of late life: Alzheimer's disease and other dementing disorders. In: Kaplan H, Sadock B, eds. Comprehensive textbook of psychiatry. Vol. 2. Baltimore: Williams & Wilkins, 1995:2562-2566.
28. Jenike MA. Psychiatric illnesses in the elderly: a review. J Geriatr Psychiatry Neurol 1996; 9:57-82.
29. Alexopoulos G. Psychiatric disorders of late life: mood disorders. In: Kaplan H, Sadock B, eds. Comprehensive textbook of psychiatry. Vol. 2. Baltimore: Williams & Wilkins, 1995: 2566-2568.
30. Longo R, Ricci C, Dalla Palma L, et al. Quantitative 31P MRS of the normal adult human brain. Assessment of interindividual differences and ageing effects. NMR Biomed 1993; 6:53-57.
31. Smith CD, Pettigrew LC, Avison MJ, et al. Frontal lobe phosphorus metabolism and neuropsychological function in aging and in Alzheimer's disease. Ann Neurol 1995; 38:194-201.
32. Charles HC, Lazeyras F, Krishnan KR, et al. Proton spectroscopy of human brain: effects of age and sex. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18:995-1004.
33. Saunders D, Howe F, van den Boogaart A, et al. Ageing of the human adult brain: in vivo quantitation of metabolic content with proton magnetic resonance spectroscopy, In: ISMRM: Third Annual Meeting and Exhibition. Nice, France, August 19-25, 1995:1804.
34. Chang L, Ernst T, Poland RE, et al. In vivo proton magnetic resonance spectroscopy of the normal aging human brain. Life Sci 1996; 58:2049-2056.
35. Pfefferbaum A, Adalsteinsson E, Spielman D, et al. In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging. Magn Reson Med 1999; 41:276-284.
36. Brooks JCW, Roberts N, Kemp GJ, et al. Age-related decrease in NAA concentration and NAA/creatine ratio revealed by single voxel 1H-MRS and compartmentation analysis in fifty subjects. ISMRM: Seventh Scientific Meeting and Exhibition. Philadelphia, May 22-28, 1999:1399.
37. McClure RJ, Kanfer JN, Panchalingam K, et al. Magnetic resonance spectroscopy and its application to aging and Alzheimer's disease. Neuroimaging Clin N Am 1995; 5:69-86.
38. Meyerhoff DJ, MacKay S, Constans JM, et al. Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging. Ann Neurol 1994; 36:40-47.
39. Cohen BM, Renshaw PF, Stoll AL, et al. Decreased brain choline uptake in older adults. An in vivo proton magnetic resonance spectroscopy study. JAMA 1995; 274:902-907.
40. Babb SM, Appelmans KE, Renshaw PF, et al. Differential effect of CDP-choline on brain cytosolic choline levels in younger and older subjects as measured by proton magnetic resonance spectroscopy. Psychopharmacology (Berl) 1996; 127: 88-94.
41. Tan J, Bluml S, Hoang T, et al. Lack of effect of oral choline supplement on the concentrations of choline metabolites in human brain. Magn Reson Med 1998; 39:1005-1010.
42. Dechent P, Pouwels PJW, Frahm J. Neither short-term nor long-term administration of oral choline alters metabolite concentrations in human brain. In: ISMRM: Seventh Scientific Meeting and Exhibition. Philadelphia, May 22-28, 1999:594.
43. Prasad MR, Lovell MA, Yatin M, et al. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 1998; 23:81-88.
44. Nitsch RM, Blusztajn JK, Pittas AG, et al. Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci U S A 1992; 89:1671-1675.
45. Stokes C, Hawthorne J. Reduced phosphoinositide concentrations in anterior temporal cortex of Alzheimer-diseased brains. J Neurochem 1987; 48:1018-1021.
46. Blusztajn JK, Lopez Gonzalez-Coviella I, Logue M, et al. Levels of phospholipid catabolic intermediates, glycerophosphocholine and glycerophosphoethanolamine are elevated in brains of Alzheimer's disease but not of Down's syndrome patients. Brain Res 1990; 536:240-244.
47. Jope R, Song L, Powers R. Cholinergic activation of phosphoinositide signaling is impaired in Alzheimer's disease brain. Neurobiol Aging 1997; 18:111-120.
48. Roth G, Joseph J, Mason R. Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging. Trends Neurosci 1995; 18:203-206.
49. Muller W, Eckert G, Scheuer K, et al. Effects of beta-amyloid peptides on the fluidity of membranes from frontal and parietal lobes of human brain. High potencies of A beta 1-42 and A betal-43. Amyloid 1998; 5:10-15.
50. Hirakura Y, Satoh Y, Hirashima N, et al. Membrane perturbation by the neurotoxic Alzheimer amyloid fragment beta 25-35 requires aggregation and beta-sheet formation. Biochem Mol Biol Int 1998; 46:787-794.
51. Terzi E, Holzemann G, Seelig J. Interaction of Alzheimer beta-amyloid peptide (1-40) with lipid membranes. Biochemistry 1997; 36:14845-14852.
52. Allen D, Galdzicki Z, Brining S, et al. Beta-amyloid induced increase in choline flux across PC12 cell membranes. Neurosci Lett 1997; 234:71-73.
53. Ehrenstein G, Galdzicki Z, Lange G. The choline-leakage hypothesis for the loss of acetylcholine in Alzheimer's disease. Biophys J 1997; 73:1276-1280.
54. Jagust WJ, Eberling JL, Reed BR, et al. Clinical studies of cerebral blood flow in Alzheimer's disease. Ann N Y Acad Sci 1997; 826:254-262.
55. Bartenstein P, Minoshima S, Hirsch C, et al. Quantitative assessment of cerebral blood flow in patients with Alzheimer's disease by SPECT. J Nucl Med 1997; 38:1095-1101.
56. Masterman DL, Mendez MF, Fairbanks LA, et al. Sensitivity, specificity, and positive predictive value of technetium 99-HMPAO SPECT in discriminating Alzheimer's disease from other dementias. J Geriatr Psychiatry Neurol 1997; 10:15-21.
57. Brown GG, Levine SR, Gorell JM, et al. In vivo 31P NMR profiles of Alzheimer's disease and multiple subcortical infarct dementia. Neurology 1989; 39:1423-1427.
58. Bottomley PA, Cousins JP, Pendrey DL, et al. Alzheimer dementia: quantification of energy metabolism and mobile phosphoesters with P-31 NMR spectroscopy. Radiology 1992; 183:695-699.
59. Murphy DG, Bottomley PA, Salerno JA, et al. An in vivo study of phosphorus and glucose metabolism in Alzheimer's disease using magnetic resonance spectroscopy and PET. Arch Gen Psychiatry 1993; 50:341-349.
60. Brown GG, Garcia JH, Gdowski JW, et al. Altered brain energy metabolism in demented patients with multiple subcortical ischemic lesions. Working hypotheses. Arch Neurol 1993; 50:384-388.
61. Pettegrew JW, Panchalingam K, Klunk WE, et al. Alterations of cerebral metabolism in probable Alzheimer's disease: a preliminary study. Neurobiol Aging 1994; 15:117-132.
62. Pettegrew JW, Klunk WE, Panchalingam K, et al. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. Neurobiol Aging 1995; 16:1-4.
63. Cuenod CA, Kaplan DB, Michot JL, et al. Phospholipid abnormalities in early Alzheimer's disease. In vivo phosphorus 31 magnetic resonance spectroscopy. Arch Neurol 1995; 52:89-94.
64. Gonzalez RG, Guimaraes AR, Moore GJ, et al. Quantitative in vivo 31P magnetic resonance spectroscopy of Alzheimer disease. Alzheimer Dis Assoc Disord 1996; 10:46-52.
65. Koshino Y, Murata T, Oomori M, et al. In vivo proton magnetic resonance spectroscopy in adult Down's syndrome. Biol Psychiatry 1992; 32:625-627.
66. Murata T, Koshino Y, Omori M, et al. In vivo proton magnetic resonance spectroscopy study on premature aging in adult Down's syndrome. Biol Psychiatry 1993; 34:290-297.
67. Shiino A, Matsuda M, Morikawa S, et al. Proton magnetic resonance spectroscopy with dementia. Surg Neurol 1993; 39:143-147.
68. Miller BL, Moats RA, Shonk T, et al. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 1993; 187:433-437.
69. Moats RA, Ernst T, Shonk TK, et al. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med 1994; 32:110-115.
70. Christiansen P, Schlosser A, Henriksen O. Reduced N-acetylaspartate content in the frontal part of the brain in patients with probable Alzheimer's disease. Magn Reson Imaging 1995; 13:457-462.
71. Shonk T, Moats R, Gifford P, et al. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 1995; 195:65-72.
72. MacKay S, Meyerhoff DJ, Constans JM, et al. Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging. Arch Neurol 1996; 53:167-174.
73. Kattapong VJ, Brooks WM, Wesley MH, et al. Proton magnetic resonance spectroscopy of vascular- and Alzheimer-type dementia. Arch Neurol 1996; 53:678-680.
74. Parnetti L, Lowenthal DT, Presciutti O, et al. 1H-MRS, MRI-based hippocampal volumetry, and 99mTc-HMPAO-SPECT in normal aging, age-associated memory impairment, and probable Alzheimer's disease [see comments]. J Am Geriatr Soc 1996; 44:133-138.
75. Parnetti L, Tarducci R, Presciutti O, et al. Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging. Mech Ageing Dev 1997; 97:9-14.
76. Ernst T, Chang L, Melchor R, et al. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology 1997; 203:829-836.
77. Frederick BB, Satlin A, Yurgelun-Todd DA, et al. In vivo proton magnetic resonance spectroscopy of Alzheimer's disease in the parietal and temporal lobes. Biol Psychiatry 1997; 42:147-150.
78. Lazeyras F, Charles HC, Tupler LA, et al. Metabolic brain mapping in Alzheimer's disease using proton magnetic resonance spectroscopy. Psychiatry Res 1998; 82:95-106.
79. Schuff N, Amend D, Ezekiel F, et al. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study. Neurology 1997; 49:1513-1521.
80. Pfefferbaum A, Adalsteinsson E, Spielman D, et al. In vivo brain concentrations of N-acetyl compounds, creatine, and choline in Alzheimer disease. Arch Gen Psychiatry 1999; 56:185-192.
81. Doraiswamy PM, Charles HC, Krishnan KR. Prediction of cognitive decline in early Alzheimer's disease [letter]. Lancet 1998; 352:1678.
82. Satlin A, Bodick N, Offen WW, et al. Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist. Am J Psychiatry 1997; 154:1459-1461.
83. Frederick BB, Satlin A, Wald LL, et al. Clinical response in patients with Alzheimer's disease treated with Xanomeline correlates with a decrease in Cho/Cre: a 1H CSI study. In: ISMRM: Sixth Scientific Meeting and Exhibition. Sydney, Australia, April 18-24, 1998:727.
84. Yu X, Krishnan KRR, Mintzer J, et al. Donepezil's effect on N-acetyl aspartate levels of Alzheimer's patients using proton magnetic resonance spectroscopy. In: ISMRM: Seventh Scientific Meeting and Exhibition. Philadelphia, May 22-28, 1999:1434.
85. Moore CM, Christensen JD, Lafer B, et al. Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: a phosphorous-31 magnetic resonance spectroscopy study. Am J Psychiatry 1997; 154:116-118.
86. Volz HP, Rzanny R, Riehemann S, et al. 31P magnetic resonance spectroscopy in the frontal lobe of major depressed patients. Eur Arch Psychiatry Clin Neurosci 1998; 248:289-295.
87. Janowsky DS, el-Yousef MK, Davis JM, et al. A cholinergic-adrenergic hypothesis of mania and depression. Lancet 1972; 2:632-635.
88. Krishnan KR, McDonald WM, Doraiswamy PM, et al. Neuroanatomical substrates of depression in the elderly. Eur Arch Psychiatry Clin Neurosci 1993; 243:41-46.
89. Hetherington HP, Pan JW, Mason GF, et al. Quantitative 1H spectroscopic imaging of human brain at 4.1 T using image segmentation. Magn Reson Med 1996; 36:21-29.
90. Renshaw PF, Lafer B, Babb SM, et al. Basal ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 1997; 41:837-843.
91. Hay D. Geriatric psychiatry: treatment: electroconvulsive therapy. In: Kaplan H, Sadock B, eds. Comprehensive textbook of psychiatry. Vol. 2. Baltimore: Williams & Wilkins, 1995:2616-2620.
92. Petroff OA, Prichard JW, Ogino T, et al. Combined 1H and 31P nuclear magnetic resonance spectroscopic studies of bicuculline-induced seizures in vivo. Ann Neurol 1986; 20:185-193.
93. Felber SR, Pycha R, Hummer M, et al. Localized proton and phosphorus magnetic resonance spectroscopy following electroconvulsive therapy. Biol Psychiatry 1993; 33:651-654.
94. Ende G, Braus DF, Kühnen J, et al. Proton MRSI in depressed patients undergoing electroconvulsive therapy: is Ch increased by ECT? In: ISMRM: Fifth Scientific Meeting and Exhibition. Vancouver, British Columbia, April 12-18, 1997:1167.
95. Ende G, Braus DF, Kühnen J, et al. Monitoring the effects of rapid transcranial magnetic stimulation in comparison to electroconvulsive therapy by means of multislice 1H MRSI. In: ISMRM: Sixth Scientific Meeting and Exhibition. Sydney, Australia, April 18-24, 1998:506.
96. Ende G, Braus DF, Walter S, et al. Investigation of hippocampal choline in depression. In: ISMRM: Seventh Scientific Meeting and Exhibition. Philadelphia, May 22-28, 1999:1411.